In addition to his presentation, Dr. Stauffer also serves as an event co-chair and on the conference’s Scientific Advisory Board.
According to the press release from Cara last week, "Dr. Stauffer will deliver opening remarks and the opening address, during which he will discuss kappa opioid receptor agonism as a new approach to managing acute and chronic pain. This discussion will highlight positive clinical trial results and human abuse liability data for CR845, the Company's first-in-class peripherally selective kappa opioid agonist. To date, results support the view that CR845 is unlikely to be recreationally abused or lead to physical dependence."
Also, be sure to subscribe to one or more of our free newsletters so you never miss an important update. If you haven't already, connect with The Daily Marijuana Observer on Facebook, Twitter, and Instagram.
I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I have no business relationship with any company whose stock is mentioned in this article.
The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.